Inpatient Blood Glucose Control in Taichung Veterans General Hospital

January 4, 2020 updated by: Taichung Veterans General Hospital

The Effects of Glucose Control and Monitor on Inflammation in the Hospitalized Patients With Hyperglycemia

This study will be conducted in the ward of Taichung Veterans General Hospital. The patient with hyperglycemia in hospitalization will be enrolled by glucose management team.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This study will be conducted in the ward of Taichung Veterans General Hospital. The type 2 diabetic patient with hyperglycemia in hospitalization are candidates. The glucose will be controlled using the insulin protocal based on the glucose monitor systems. We will assess the effects of insulin protocal and glucose monitor system on the inpatient with hyperglycemia.

Study Type

Interventional

Enrollment (Anticipated)

600

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Taiwan
      • Taichung, Taiwan, 40705
        • Recruiting
        • Taichung Veterans General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Type 2 diabetic inpatient
  • Fasting glucose >140 mg/dl or random glucose >180 mg/dl

Exclusion Criteria:

  • incooperative for glucose monitor
  • refusal of insulin
  • pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Insulin protocal with CGM
Insulin protocal with continue glucose monitor
Device: CONTINUE GLUCOSE MONITOR
Continue glucose monitor
Procedure: Insulin protocal
Using insulin protocal based on glucose monitor
Active Comparator: Insulin protocal
Insulin protocal with convential glucose monitor
Procedure: Insulin protocal
Using insulin protocal based on glucose monitor
No Intervention: Convential treatment
Convential insulin treatment and glucose monitor

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Glucose target
Time Frame: 6 days
The ratio of glucose less than 180 mg/dl
6 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fasting glucose target
Time Frame: 6 days
the ratio of fasting glucose less than 140 mg/dl
6 days
Hypoglycemia
Time Frame: times
symptoms or less than 70
times
Vascular Cell Adhesion Molecule 1 (VCAM-1)
Time Frame: 6 days
Inflammation
6 days
Brain-Derived Neurotrophic Factor (BDNF)
Time Frame: 6 days
Psychological assessment
6 days
Orexin-A
Time Frame: 6 days
Psychological assessment
6 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Taichung Veterans General Hospital

Investigators

  • Principal Investigator: I-Te Lee, MD,PhD, Taichung Veterans General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2016

Primary Completion (Anticipated)

December 1, 2022

Study Completion (Anticipated)

December 1, 2025

Study Registration Dates

First Submitted

August 26, 2016

First Submitted That Met QC Criteria

August 26, 2016

First Posted (Estimate)

September 1, 2016

Study Record Updates

Last Update Posted (Actual)

January 7, 2020

Last Update Submitted That Met QC Criteria

January 4, 2020

Last Verified

December 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CF16199B

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

No plan to make individual participant data (IPD) available

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HYPERGLYCEMIA

Clinical Trials on CONTINUE GLUCOSE MONITOR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe